Kind Pharmaceutical LLC

Established in 2014 and headquartered in Hangzhou, China, Kind Pharmaceutical LLC is a multinational pharmaceutical company engaged in the research and development of innovative therapeutics. The company operates a U. S. research facility located at the Pharmaceutical Research Center in San Francisco and a China site in the Community of Industries in Zhejiang Province.

In November 2025, it closed a series C funding round from Grand Invest, Tppoly Capital, Xiamen C&D Emerging Industry Equity Investment, Tailong VC, ZJ Biomedicine and High-end Equipment Industry Fund and other investors. The company's products include AND17, AND19, Antibody-drug conjugates (ADCs), and AND021. AND017 is a small molecular inhibitor of prolyl hydroxylase, mimics the natural physiological regulation under hypoxia condition to stabilize HIF and promote the production of red blood cells to treat anemia. AND019 is a novel third generation selective estrogen receptor degrader, which is a competitive antagonist of estrogen receptor (ER) by binding with ER to mediate its degradation.

AND021 program is currently under clinical candidate nomination step. It will be developed for HIF-2-dependent renal cell carcinoma and other difficult-to-treat diseases. The company primarily generates revenue through research collaborations, licensing agreements and payments related to its drug discovery and development programs. Following the series C funding round, Kind Pharmaceutical LLC plans to advance its ongoing global clinical programs, expand its R&D capabilities and further develop its pipeline of small-molecule and ADC therapeutics to address anemia and oncology indications.